Increased peripheral blood leukocyte cytotoxic activity in cancer patients during the continuous intravenous administration of recombinant human tumor necrosis factor

Paul S. Charnetsky, Richard A. Greisman, Sydney E. Salmon, Evan M Hersh, Philip Scuderi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Peripheral blood leukocyte cytotoxic activity was studied in cancer patients being treated with a continuous 5-day intravenous infusion of recombinant human tumor necrosis factor (TNF) at a dose of 40 μg/m2/day. All of the nine patients tested experienced a marked increase in circulating leukocyte cytotoxic activity over the 5-day course of treatment. The increase in cytotoxic activity was paralleled by an overall decrease in the number of peripheral blood leukocytes. The percentage of circulating Leu 19+ natural killer cells fell in all patients, while the numbers of both Leu 4+ T cells and Leu 19+/Leu 4+ cytotoxic T cells remained constant. Our findings suggest that the intravenous administration of recombinant TNF may be accompanied by an immunoenhancement due either to an improvement in cytotoxic cell function or to alterations in the trafficking of leukocytes.

Original languageEnglish (US)
Pages (from-to)34-38
Number of pages5
JournalJournal of Clinical Immunology
Volume9
Issue number1
DOIs
StatePublished - Jan 1989

Fingerprint

Intravenous Administration
Leukocytes
Neoplasms
T-Lymphocytes
Intravenous Infusions
Natural Killer Cells
Tumor Necrosis Factor-alpha
human TNF protein
Therapeutics

Keywords

  • cytotoxic leukocytes
  • natural killer cells
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Increased peripheral blood leukocyte cytotoxic activity in cancer patients during the continuous intravenous administration of recombinant human tumor necrosis factor. / Charnetsky, Paul S.; Greisman, Richard A.; Salmon, Sydney E.; Hersh, Evan M; Scuderi, Philip.

In: Journal of Clinical Immunology, Vol. 9, No. 1, 01.1989, p. 34-38.

Research output: Contribution to journalArticle

@article{0ea92d4528e848c8be3130a108ebf51d,
title = "Increased peripheral blood leukocyte cytotoxic activity in cancer patients during the continuous intravenous administration of recombinant human tumor necrosis factor",
abstract = "Peripheral blood leukocyte cytotoxic activity was studied in cancer patients being treated with a continuous 5-day intravenous infusion of recombinant human tumor necrosis factor (TNF) at a dose of 40 μg/m2/day. All of the nine patients tested experienced a marked increase in circulating leukocyte cytotoxic activity over the 5-day course of treatment. The increase in cytotoxic activity was paralleled by an overall decrease in the number of peripheral blood leukocytes. The percentage of circulating Leu 19+ natural killer cells fell in all patients, while the numbers of both Leu 4+ T cells and Leu 19+/Leu 4+ cytotoxic T cells remained constant. Our findings suggest that the intravenous administration of recombinant TNF may be accompanied by an immunoenhancement due either to an improvement in cytotoxic cell function or to alterations in the trafficking of leukocytes.",
keywords = "cytotoxic leukocytes, natural killer cells, Tumor necrosis factor",
author = "Charnetsky, {Paul S.} and Greisman, {Richard A.} and Salmon, {Sydney E.} and Hersh, {Evan M} and Philip Scuderi",
year = "1989",
month = "1",
doi = "10.1007/BF00917125",
language = "English (US)",
volume = "9",
pages = "34--38",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Increased peripheral blood leukocyte cytotoxic activity in cancer patients during the continuous intravenous administration of recombinant human tumor necrosis factor

AU - Charnetsky, Paul S.

AU - Greisman, Richard A.

AU - Salmon, Sydney E.

AU - Hersh, Evan M

AU - Scuderi, Philip

PY - 1989/1

Y1 - 1989/1

N2 - Peripheral blood leukocyte cytotoxic activity was studied in cancer patients being treated with a continuous 5-day intravenous infusion of recombinant human tumor necrosis factor (TNF) at a dose of 40 μg/m2/day. All of the nine patients tested experienced a marked increase in circulating leukocyte cytotoxic activity over the 5-day course of treatment. The increase in cytotoxic activity was paralleled by an overall decrease in the number of peripheral blood leukocytes. The percentage of circulating Leu 19+ natural killer cells fell in all patients, while the numbers of both Leu 4+ T cells and Leu 19+/Leu 4+ cytotoxic T cells remained constant. Our findings suggest that the intravenous administration of recombinant TNF may be accompanied by an immunoenhancement due either to an improvement in cytotoxic cell function or to alterations in the trafficking of leukocytes.

AB - Peripheral blood leukocyte cytotoxic activity was studied in cancer patients being treated with a continuous 5-day intravenous infusion of recombinant human tumor necrosis factor (TNF) at a dose of 40 μg/m2/day. All of the nine patients tested experienced a marked increase in circulating leukocyte cytotoxic activity over the 5-day course of treatment. The increase in cytotoxic activity was paralleled by an overall decrease in the number of peripheral blood leukocytes. The percentage of circulating Leu 19+ natural killer cells fell in all patients, while the numbers of both Leu 4+ T cells and Leu 19+/Leu 4+ cytotoxic T cells remained constant. Our findings suggest that the intravenous administration of recombinant TNF may be accompanied by an immunoenhancement due either to an improvement in cytotoxic cell function or to alterations in the trafficking of leukocytes.

KW - cytotoxic leukocytes

KW - natural killer cells

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0024561677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024561677&partnerID=8YFLogxK

U2 - 10.1007/BF00917125

DO - 10.1007/BF00917125

M3 - Article

C2 - 2784796

AN - SCOPUS:0024561677

VL - 9

SP - 34

EP - 38

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 1

ER -